| Safety and activity of anti–PD-L1 antibody in patients with advanced cancer JR Brahmer, SS Tykodi, LQM Chow, WJ Hwu, SL Topalian, P Hwu, ... New England Journal of Medicine 366 (26), 2455-2465, 2012 | 8938 | 2012 |
| Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients V Gopalakrishnan, CN Spencer, L Nezi, A Reuben, MC Andrews, ... Science 359 (6371), 97-103, 2018 | 4035 | 2018 |
| Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes ME Dudley, JR Wunderlich, PF Robbins, JC Yang, P Hwu, ... Science 298 (5594), 850-854, 2002 | 3764 | 2002 |
| A randomized trial of bevacizumab, an anti–vascular endothelial growth factor antibody, for metastatic renal cancer JC Yang, L Haworth, RM Sherry, P Hwu, DJ Schwartzentruber, ... New England Journal of Medicine 349 (5), 427-434, 2003 | 3593 | 2003 |
| Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma SA Rosenberg, JC Yang, DJ Schwartzentruber, P Hwu, FM Marincola, ... Nature medicine 4 (3), 321-327, 1998 | 2259 | 1998 |
| Chimeric antigen receptor T-cell therapy—assessment and management of toxicities SS Neelapu, S Tummala, P Kebriaei, W Wierda, C Gutierrez, FL Locke, ... Nature reviews Clinical oncology 15 (1), 47-62, 2018 | 2171 | 2018 |
| Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma GQ Phan, JC Yang, RM Sherry, P Hwu, SL Topalian, ... Proceedings of the National Academy of Sciences 100 (14), 8372-8377, 2003 | 1945 | 2003 |
| B cells and tertiary lymphoid structures promote immunotherapy response BA Helmink, SM Reddy, J Gao, S Zhang, R Basar, R Thakur, K Yizhak, ... Nature 577 (7791), 549-555, 2020 | 1814 | 2020 |
| A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer MH Kershaw, JA Westwood, LL Parker, G Wang, Z Eshhar, ... Clinical cancer research 12 (20), 6106-6115, 2006 | 1500 | 2006 |
| Loss of PTEN promotes resistance to T cell–mediated immunotherapy W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ... Cancer discovery 6 (2), 202-216, 2016 | 1408 | 2016 |
| PD-L1 expression in triple-negative breast cancer EA Mittendorf, AV Philips, F Meric-Bernstam, N Qiao, Y Wu, S Harrington, ... Cancer immunology research 2 (4), 361-370, 2014 | 1352 | 2014 |
| Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy J Gao, LZ Shi, H Zhao, J Chen, L Xiong, Q He, T Chen, J Roszik, ... Cell 167 (2), 397-404. e9, 2016 | 1245 | 2016 |
| gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma DJ Schwartzentruber, DH Lawson, JM Richards, RM Conry, DM Miller, ... New England Journal of Medicine 364 (22), 2119-2127, 2011 | 1098 | 2011 |
| A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade L Jerby-Arnon, P Shah, MS Cuoco, C Rodman, MJ Su, JC Melms, ... Cell 175 (4), 984-997. e24, 2018 | 1086 | 2018 |
| Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer JC Yang, RM Sherry, SM Steinberg, SL Topalian, DJ Schwartzentruber, ... Journal of clinical oncology 21 (16), 3127-3132, 2003 | 1015 | 2003 |
| BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma DT Frederick, A Piris, AP Cogdill, ZA Cooper, C Lezcano, CR Ferrone, ... Clinical cancer research 19 (5), 1225-1231, 2013 | 999 | 2013 |
| T helper 17 cells promote cytotoxic T cell activation in tumor immunity N Martin-Orozco, P Muranski, Y Chung, XO Yang, T Yamazaki, S Lu, ... Immunity 31 (5), 787-798, 2009 | 972 | 2009 |
| Indoleamine 2, 3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation P Hwu, MX Du, R Lapointe, M Do, MW Taylor, HA Young The Journal of Immunology 164 (7), 3596-3599, 2000 | 960 | 2000 |
| Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade PL Chen, W Roh, A Reuben, ZA Cooper, CN Spencer, PA Prieto, JP Miller, ... Cancer discovery 6 (8), 827-837, 2016 | 958 | 2016 |
| Phase I Study of the Intravenous Administration of Attenuated Salmonella typhimurium to Patients With Metastatic Melanoma JF Toso, VJ Gill, P Hwu, FM Marincola, NP Restifo, DJ Schwartzentruber, ... Journal of clinical oncology 20 (1), 142-152, 2002 | 883 | 2002 |
